Skip to main content
letter
. 2024 Sep 28;13(11):599–601. doi: 10.1093/jpids/piae098

Figure 1.

Figure 1.

Solicited adverse events in (A) adolescent participants who received 2.5 × 1010 vp Ad26.COV2.S vaccine or placebo; (B) healthy adults aged 18–55 and ≥65 years who received 5 × 1010 vp Ad26.COV2.S vaccine; and (C) healthy adults aged 18–25 years who received 5 × 1010 vp Ad26.COV2.S vaccine. The number of participants reporting each grade is shown within each section of bars. Abbreviations: vp, viral particles.